Copyright
©The Author(s) 2018.
World J Gastrointest Endosc. Dec 16, 2018; 10(12): 422-441
Published online Dec 16, 2018. doi: 10.4253/wjge.v10.i12.422
Published online Dec 16, 2018. doi: 10.4253/wjge.v10.i12.422
STUDY | SITE | POPULATION | INTERVENTION (ITT/PP) | COMPARISON (ITT/PP) | OUTCOMES |
Regev et al[34] | 1 | 29 to 86 y | Pico-Salax (1+1+1)/0 sachets | New-Meroken® 3/0 L | Bowel cleansing quality |
Israel | + (200/h for 16h)/0 mL of water | Cecal intubation | |||
ITT: 68 | + clear liquid diet | + clear liquid diet | General discomfort | ||
PP: 68 | 39/39 | 29/29 | Medication Intake | ||
Adverse events | |||||
Lawrance et al[35] | 1 | 18 to 75 y | Pico® (1+1)/0 sachets for morning procedure or | ColonLytely® 4/0 L for morning procedure or | Bowel cleansing quality |
Australia | |||||
Pico 1/1 sachets for afternoon procedure | ColonLytely® 4/0 L for afternoon procedure | ||||
+ liquid | + clear liquid 2/0 | ||||
ITT: 634 | + low residue diet | 284/279 | Medication Intake | ||
PP: 625 | 171/169 | ||||
CB fleet® (45+45)/0 mL | |||||
+ (750+750)/0 mL of water for morning procedure or | Mucosal inflammation | ||||
CB fleet® 45/45 mL | |||||
+ 750/750 mL of water for afternoon procedure | |||||
+ low residue diet | |||||
179/177 | |||||
Kao et al[36] | 1 | 18 to 75 y | SPMC (1+1+MC)/0 sachets for morning procedure or | PEG 4/0 L for morning procedure or | Bowel cleansing quality |
Canada | |||||
SPMC (1+1)/MC sachets for afternoon procedure | PEG 2/2 L for afternoon procedure | Bowel cleansing quality according to the procedure time | |||
ITT: 834 | + liquid | + liquid | Tolerability | ||
PP: 790 | + clear liquid diet | + clear liquid diet | |||
194/194 | 218/210 | Adherence | |||
NaP 45/45/0 mL for morning procedure or | PEG 2/0 L + bisacodyl 20/0 mg for morning procedure or | Sleeping hours | |||
NaP 0/45/45 mL for afternoon procedure | PEG 0/2 L + bisacodyl 20/0 mg for afternoon procedure | Willingness to reuse | |||
+ liquid | + liquid | Safety | |||
+ clear liquid diet | + clear liquid diet | ||||
164/164 | 214/210 | Ischemic colitis | |||
Katz et al[15] | 12 | 18 to 80 y | Prepopik® (1+1)/0 sachets | Half-Lytely e bisacodyl Tablets® 2/0 L | Bowel cleansing quality |
USA | |||||
+ (1200+720)/0 mL of liquid | + 10/0 mg bisacodyl | Acceptability | |||
Tolerability | |||||
ITT: 603 | + clear liquid diet | + clear liquid diet | Medication Intake | ||
PP: 598 | Ease to use medication | ||||
300/296 | 303/302 | General experience | |||
Taste | |||||
Willingness to reuse | |||||
Adverse events | |||||
Manes et al[37] | 3 | 18 to 85 y | CitraFleet® (1+1)/0 sachets | Moviprep® 2/0 L | Bowel cleansing quality |
Italy | |||||
+ 3/0 L of liquid for morning procedure or | + 1/0 L of liquid for morning procedure or | Bowel cleansing quality of right colon | |||
ITT: 293 | CitraFleet® 1/1 sachets | Moviprep® 1/1 L | Polyps detected | ||
PP: 285 | + 1.5/1.5 L of liquid for afternoon procedure | + 500/500 mL of liquid for afternoon procedure | Acceptance | ||
+ low-fiber diet | + low-fiber diet | Tolerability | |||
145/140 | 148/145 | Adherence | |||
Adverse events | |||||
Rex et al[15] | 10 | 18 to 80 y | Prepopik® 1/1 sachets | Half-Lytely e bisacodyl Tablets® 2/0 L | Bowel cleansing quality |
USA | |||||
+ 1200/720 mL of liquid | + bisacodyl 10/0 mg | Acceptability | |||
+ clear liquid diet | Tolerability | ||||
ITT: 608 | + clear liquid diet | Ease to use medication | |||
PP: 601 | Medication Intake | ||||
Taste | |||||
NA/305 | NA/298 | Willingness to reuse medication | |||
Adverse events | |||||
Colonoscopy before | |||||
Jeon et al[38] | 1 | 20 to 80 y | Picolight powder® (1+1)/1 sachet | Coolprep powder® 1/1 L | Bowel cleansing quality |
South Korea | |||||
+ (1+1)/1 L of water | + 500/500 mL of water | Cecal intubation | |||
+ low-fiber diet | + low-fiber diet | Withdrawal time | |||
ITT: 430 | ADR | ||||
PP: 388 | PDR | ||||
Tolerability | |||||
215/195 | 215/193 | Satisfaction | |||
Adverse events | |||||
Kang et al[39] | 1 | 18 to ou mais | Picolight® 0/(1+1) | Colyte® 2/2 L | Bowel cleansing quality |
South Korea | |||||
+ 0/≥ 1 L of water | + low-fiber diet | Tolerability | |||
ITT: 197 | + low-fiber diet | 99/99 | Adverse events | ||
PP: 197 | 98/98 | Sleep time quantity | |||
PDR | |||||
ADR | |||||
Kim et al[40] | 1 | 18 to 75 y | SPMC 1/1 sachets | PEG 0/4 L | Bowel cleansing quality |
South Korea | |||||
+ 1/1 L of liquid | Adherence | ||||
+ low-fiber diet | + low-fiber diet | Medication Intake | |||
ITT: 200 | 50/50 | 50/50 | |||
PP: 200 | SPMC (1+1)/1 sachets | PEG 2/2 L | Tolerability | ||
+ (1+1)/1 L of liquid | Taste | ||||
+ low-fiber diet | + low-fiber diet | Biochemical changes | |||
50/50 | 50/50 | Adverse events | |||
Kim et al[41] | 1 | 18 to 80 y | Picolight (1+1)/0 sachets | Standard PEG 4/0 L | Acceptability |
South Korea | + 2L of water | Adherence to instructions | |||
ITT: 194 | + bisacodyl 10/0 mg | + bisacodyl 10/0 mg | Bowel cleansing quality | ||
PP: 184 | + low-fiber diet (ZeroCol) | + semi-fluid diet | Adverse events | ||
97/94 | 97/90 | Willingness to reuse medication | |||
Leitao et al[28] | 3 | 18 to 80 y | CitraFleet® 1/1 sachets | Enddealk® 2/1L | Bowel cleansing quality |
Norway | |||||
+ 2/2 L of water | + 0/1 L of liquid | Tolerability | |||
ITT: 368 | + no-grains diet | + diet without crops | Adherence | ||
PP: 368 | PDR | ||||
179/179 | 189/189 | Cecal intubation time | |||
Cecal intubation | |||||
Kim et al[29] | 13 | 20 to 75 y | sachets | Standard PEG 2/2 L | Bowel cleansing quality |
South Korea | |||||
+ 2/2 L of water | no bisacodyl | Satisfaction | |||
+ bisacodyl 10/0 mg | + low-fiber diet | Tolerability | |||
+ low-fiber diet | Medication Intake | ||||
ITT: 387 | 193/181 | 194 / 184 | Ease to use | ||
PP: 365 | Taste | ||||
Willingness to reuse | |||||
Adverse events | |||||
Munsterman et al[30] | 1 | 18 to 80 y | Picoprep® 1/1 sachets for morning procedure or | Kleanprep® 3/1 L for morning procedure or | Bowel cleansing quality |
Netherlands | |||||
ITT: 173 | Picoprep® 1/1 sachets for afternoon procedure | Kleanprep® 2/2 L for afternoon procedure | |||
PP: 172 | + 2/2 L of water | + additional liquid | Tolerability | ||
+ low-fiber diet | + low-fiber diet | ||||
88/87 | 85/85 | ||||
Pohl et al[31] | 17 | 40 to 80 y | CitraFleet® (1+1)/0 sachets | Moviprep® 1/1 L | Patients with at least one polyp or flat lesion |
Germany | |||||
ITT: 399 | + 250mL/h of water after sachet | + 500/500 mL of liquid | Patients with at least one adenoma | ||
PP: 398 | Cancer detection rate | ||||
+ fibers restriction diet | + fibers restriction diet | Flat lesion detection rate | |||
NA/197 | NA/201 | Advanced lesions detection rate | |||
Yoo et al[32] | 1 | 18 to 80 y | Picolight® 1/1 sachets | Coolprep® 1/1 L | Bowel cleansing quality |
South Korea | |||||
+ 1/1 L of water | + 500/500 mL of water | Bubble score | |||
ITT: 200 | + low-fiber diet | + low-fiber diet | Tolerability | ||
PP: 200 | |||||
100/100 | 100/100 | Satisfaction | |||
Kojecky et al[33] | 3 | 18 to 99 y | Picoprep® 2/0 sachets | Fortrans™ 4/0 L | Length of preparation |
Czech Republic | + 2L of water | 94/102 | |||
ITT: 612 | 92/102 | Fortrans™ 3/1 L | Time to colonoscopy | ||
87/102 | |||||
PP: 584 | OR | Moviprep™ 2/0 L | |||
+ 1/0 L of fluids | |||||
Picoprep® 1/1 sachets | 96/102 | Bowel cleansing quality | |||
+ 1/1 L of water | |||||
86/102 | Moviprep™ 1/1 | ||||
+ 0.5/0.5 L of fluids | |||||
93/102 | Tolerability score | ||||
+ low residue diet | + low residue diet |
- Citation: Rocha RSP, Ribeiro IB, de Moura DTH, Bernardo WM, Minata MK, Morita FHA, Aquino JCM, Baba ER, Miyajima NT, de Moura EGH. Sodium picosulphate or polyethylene glycol before elective colonoscopy in outpatients? A systematic review and meta-analysis. World J Gastrointest Endosc 2018; 10(12): 422-441
- URL: https://www.wjgnet.com/1948-5190/full/v10/i12/422.htm
- DOI: https://dx.doi.org/10.4253/wjge.v10.i12.422